AstraZeneca gets an early green light on BTK blockbuster hopeful Calquence
Image: Pascal Soriot AP Images
AstraZeneca $AZN has received an early OK from regulators to sell its cancer drug acalabrutinib, now under the brand name Calquence.
The BTK inhibitor — being set up as a rival to Imbruvica from AbbVie and J&J — is a treatment for cancer patients with mantle cell lymphoma, a rare B-cell non-Hodgkin lymphoma. The drug will be used as a second-line therapy for relapsed/refractory mantle cell lymphoma.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.